A longitudinal study of ABC transporter expression in canine multicentric lymphoma

Veterinary Journal

Volumn 205, Issue 2, 2015, Pages 263-271

  Zandvliet, M ^a   Teske, E ^a   Schrickx, J A ^b   Mol, J A ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

ABC transporters; Canine; Lymphoma; Multidrug resistance; P glycoprotein

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISOLONE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DOG; DRUG EFFICACY; FEMALE; IMMUNOPHENOTYPING; LONGITUDINAL STUDY; LYMPHOMA; MALE; MULTIPLE CANCER; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; UPREGULATION; ANIMAL; DOG DISEASES; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; VETERINARY;

CANIS FAMILIARIS;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; LONGITUDINAL STUDIES; LYMPHOMA; MALE;

EID: 84937501637     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2014.11.002     Document Type: Article

References (49)

1. Bergman P.J., Ogilvie G.K., Powers B.E. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: Sequential analysis and predictive ability in dogs with lymphoma. Journal of Veterinary Internal Medicine 1996, 10:354-359.
2. Burger H., Foekens J.A., Look M.P., Meijer-van Gelder M.E., Klijn J.G., Wiemer E.A., Stoter G., Nooter K. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response. Clinical Cancer Research 2003, 9:827-836.
3. Dhaliwal R.S., Kitchell B.E., Ehrhart E., Valli V.E., Dervisis N.G. Clinicopathologic significance of histologic grade, Pgp, and p53 expression in canine lymphoma. Journal of the American Animal Hospital Association 2013, 49:175-184.
4. Elliott A.M., Al-Hajj M.A. ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Molecular Cancer Research 2009, 7:79-87.
5. Garrett L.D., Thamm D.H., Chun R., Dudley R., Vail D.M. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 2002, 16:704-709.
6. Gavazza A., Lubas G., Valori E., Gugliucci B. Retrospective survey of malignant lymphoma cases in the dog: Clinical, therapeutical and prognostic features. Veterinary Research Communications 2008, 32:S291-S293.
7. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nature Reviews. Cancer 2002, 2:48-58.
8. Gromicho M., Dinis J., Magalhaes M., Fernandes A.R., Tavares P., Laires A., Rueff J., Rodrigues A.S. Development of imatinib and dasatinib resistance: Dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leukemia and Lymphoma 2011, 52:1980-1990.
9. Henderson M.J., Haber M., Porro A., Munoz M.A., Iraci N., Xue C., Murray J., Flemming C.L., Smith J., Fletcher J.I., et al. ABCC multidrug transporters in childhood neuroblastoma: Clinical and biological effects independent of cytotoxic drug efflux. Journal of the National Cancer Institute 2011, 103:1236-1251.
10. Hifumi T., Miyoshi N., Kawaguchi H., Nomura K., Yasuda N. Immunohistochemical detection of proteins associated with multidrug resistance to anti-cancer drugs in canine and feline primary pulmonary carcinoma. The Journal of Veterinary Medical Science/The Japanese Society of Veterinary Science 2010, 72:665-668.
11. Honjo Y., Hrycyna C.A., Yan Q.W., Medina-Perez W.Y., Robey R.W., van de Laar A., Litman T., Dean M., Bates S.E. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Research 2001, 61:6635-6639.
12. Honscha K.U., Schirmer A., Reischauer A., Schoon H.A., Einspanier A., Gabel G. Expression of ABC-transport proteins in canine mammary cancer: Consequences for chemotherapy. Reproduction in Domestic Animals 2009, 44:218-223.
13. Kawanobe T., Kogure S., Nakamura S., Sato M., Katayama K., Mitsuhashi J., Noguchi K., Sugimoto Y. Expression of human ABCB5 confers resistance to taxanes and anthracyclines. Biochemical and Biophysical Research Communications 2012, 418:736-741.
14. Kool M., van der Linden M., de Haas M., Scheffer G.L., de Vree J.M., Smith A.J., Jansen G., Peters G.J., Ponne N., Scheper R.J., et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:6914-6919.
15. Kourti M., Vavatsi N., Gombakis N., Sidi V., Tzimagiorgis G., Papageorgiou T., Koliouskas D., Athanassiadou F. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. International Journal of Hematology 2007, 86:166-173.
16. Lage H. An overview of cancer multidrug resistance: A still unsolved problem. Cellular and Molecular Life Sciences 2008, 65:3145-3167.
17. Lal S., Mahajan A., Chen W.N., Chowbay B. Pharmacogenetics of target genes across doxorubicin disposition pathway: A review. Current Drug Metabolism 2010, 11:115-128.
18. Lee J.J., Hughes C.S., Fine R.L., Page R.L. P-glycoprotein expression in canine lymphoma: A relevant, intermediate model of multidrug resistance. Cancer 1996, 77:1892-1898.
19. Ma L., Pratt S.E., Cao J., Dantzig A.H., Moore R.E., Slapak C.A. Identification and characterization of the canine multidrug resistance-associated protein. Molecular Cancer Therapeutics 2002, 1:1335-1342.
20. Manceau S., Giraud C., Decleves X., Batteux F., Chereau C., Chouzenoux S., Scherrmann J.M., Weill B., Perrot J.Y., Treluyer J.M. Expression and induction by dexamethasone of ABC transporters and nuclear receptors in a human T-lymphocyte cell line. Journal of Chemotherapy 2012, 24:48-55.
21. Marconato L., Stefanello D., Valenti P., Bonfanti U., Comazzi S., Roccabianca P., Caniatti M., Romanelli G., Massari F., Zini E. Predictors of long-term survival in dogs with high-grade multicentric lymphoma. Journal of the American Veterinary Medical Association 2011, 238:480-485.
22. Martin P., Riley R., Back D.J., Owen A. Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. British Journal of Pharmacology 2008, 153:805-819.
23. Mealey K.L. ABCG2 transporter: Therapeutic and physiologic implications in veterinary species. Journal of Veterinary Pharmacology and Therapeutics 2012, 35:105-112.
24. Mealey K.L., Fidel J., Gay J.M., Impellizeri J.A., Clifford C.A., Bergman P.J. ABCB1-1μδ polymorphism can predict hematologic toxicity in dogs treated with vincristine. Journal of Veterinary Internal Medicine 2008, 22:996-1000.
25. Nambaru P.K., Hubner T., Kock K., Mews S., Grube M., Payen L., Guitton J., Sendler M., Jedlitschky G., Rimmbach C., et al. Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2011, 39:132-139.
26. TNM Classification of Tumours in Domestic Animals 1980, World Health Organization (WHO), Geneva, Switzerland, 53 pp. L.N. Owen (Ed.).
27. Page R.L., Hughes C.S., Huyan S., Sagris J., Trogdon M. Modulation of P-glycoprotein-mediated doxorubicin resistance in canine cell lines. Anticancer Research 2000, 20:3533-3538.
28. Peters I.R., Peeters D., Helps C.R., Day M.J. Development and application of multiple internal reference (housekeeper) gene assays for accurate normalisation of canine gene expression studies. Veterinary Immunology and Immunopathology 2007, 117:55-66.
29. Pfaffl M.W., Horgan G.W., Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Research 2002, 30:e36.
30. Piek C.J., Rutteman G.R., Teske E. Evaluation of the results of a L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma. The Veterinary Quarterly 1999, 21:44-49.
31. Ponce F., Magnol J.P., Ledieu D., Marchal T., Turinelli V., Chalvet-Monfray K., Fournel-Fleury C. Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. The Veterinary Journal 2004, 167:158-166.
32. Price G.S., Page R.L., Fischer B.M., Levine J.F., Gerig T.M. Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. Journal of Veterinary Internal Medicine 1991, 5:259-262.
33. Simon D., Nolte I., Eberle N., Abbrederis N., Killich M., Hirschberger J. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. Journal of Veterinary Internal Medicine 2006, 20:948-954.
34. Sorenmo K., Overley B., Krick E., Ferrara T., LaBlanc A., Shofer F. Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases. Veterinary and Comparative Oncology 2010, 8:196-208.
35. Srimunta U., Sawanyawisuth K., Kraiklang R., Pairojkul C., Puapairoj A., Titipungul T., Hahnvajanawong C., Tassaneeyakul W., Wongkham C., Wongkham S., et al. High expression of ABCC1 indicates poor prognosis in intrahepatic cholangiocarcinoma. Asian Pacific Journal of Cancer Prevention 2012, 13:125-130.
36. Starkey M.P., Murphy S. Using lymph node fine needle aspirates for gene expression profiling of canine lymphoma. Veterinary and Comparative Oncology 2010, 8:56-71.
37. Steingold S.F., Sharp N.J., McGahan M.C., Hughes C.S., Dunn S.E., Page R.L. Characterization of canine MDR1 mRNA: Its abundance in drug resistant cell lines and in vivo. Anticancer Research 1998, 18:393-400.
38. Tashbaeva R.E., Hwang D.N., Song G.S., Choi N.H., Lee J.H., Lyoo Y.S., Lee S.J., Jung D.I., Kim H.Y., Sur J.H. Cellular characterization of multidrug resistance P-glycoprotein, alpha fetoprotein, and neovascular endothelium-associated antigens in canine hepatocellular carcinoma and cirrhotic liver. Veterinary Pathology 2007, 44:600-606.
39. Teske E. Canine malignant lymphoma: A review and comparison with human non-Hodgkin's lymphoma. The Veterinary Quarterly 1994, 16:209-219.
40. Teske E., van Heerde P., Rutteman G.R., Kurzman I.D., Moore P.F., MacEwen E.G. Prognostic factors for treatment of malignant lymphoma in dogs. Journal of the American Veterinary Medical Association 1994, 205:1722-1728.
41. Tomiyasu H., Goto-Koshino Y., Takahashi M., Fujino Y., Ohno K., Tsujimoto H. Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with lymphoma. The Journal of Veterinary Medical Science/The Japanese Society of Veterinary Science 2010, 72:1165-1172.
42. Vail D.M., Michels G.M., Khanna C., Selting K.A., London C.A. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0) - A Veterinary Cooperative Oncology Group (VCOG) consensus document. Veterinary and Comparative Oncology 2010, 8:28-37. Veterinary Cooperative Oncology Group.
43. Valli V.E., San Myint M., Barthel A., Bienzle D., Caswell J., Colbatzky F., Durham A., Ehrhart E.J., Johnson Y., Jones C., et al. Classification of canine malignant lymphomas according to the World Health Organization criteria. Veterinary Pathology 2011, 48:198-211.
44. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 2002, 3. RESEARCH0034.
45. Wasilewska A.M., Zoch-Zwierz W.M., Pietruczuk M. Expression of P-glycoprotein in lymphocytes of children with nephrotic syndrome treated with glucocorticoids. European Journal of Pediatrics 2006, 165:839-844.
46. Wijnholds J., Mol C.A., van Deemter L., de Haas M., Scheffer G.L., Baas F., Beijnen J.H., Scheper R.J., Hatse S., De Clercq E., et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:7476-7481.
47. Yang M., Li W., Fan D., Yan Y., Zhang X., Zhang Y., Xiong D. Expression of ABCB5 gene in hematological malignancies and its significance. Leukemia and Lymphoma 2012, 53:1211-1215.
48. Zandvliet M., Rutteman G.R., Teske E. Prednisolone inclusion in a first-line multidrug cytostatic protocol for the treatment of canine lymphoma does not affect therapy results. The Veterinary Journal 2013, 197:656-661.
49. Zandvliet M., Teske E., Schrickx J.A. Multi-drug resistance in a canine lymphoid cell line due to increased P-glycoprotein expression, a potential model for drug-resistant canine lymphoma. Toxicology in Vitro 2014, 28:1498-1506.